Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
Category: #health  By Pankaj Singh  Date: 2019-10-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech IMbrave150 study meets coprimary endpoints for HCC treatment

With growing occurrence of liver cancer cases across the globe, the need to find a solution to the ailment is rising steadily among global biotechnology and pharmaceutical firms. Various clinical trials and studies are increasingly being conducted to discover an effective treatment over this cancer.

Genentech Inc, a renowned U.S. based biotechnology company and a subsidiary of Roche Group, reportedly announced that its Phase III IMbrave150 trial, evaluating combination of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) to treat people suffering from unresectable HCC (hepatocellular carcinoma), who did not receive any prior systemic therapy.

The treatment met both of the study’s co-primary endpoints, showcasing clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to standard-of-care sorafenib. 

Safety for the Avastin and Tecentriq combination was observed to be consistent with the pre-known safety profiles of individual medicines, with no identification of new safety signals. IMbrave150 trial data would be showcased during a forthcoming medical meeting.   

Chief Medical Officer and Head of Global Product Development, Levi Garraway, M.D., Ph.D., stated that the company is thrilled with the outcomes of its study assessing the Tecentriq-Avastin combination, which becomes the first therapy in over a decade to enhance overall survival in patients suffering from unresectable hepatocellular carcinoma who did not undergo any prior systemic therapy.       

Garraway added that HCC is a prominent cause of death across the world, specifically in Asia, which makes this study a vital step in the company’s mission to address unmet medical demands for patients across the globe. The company would submit data from the study to global health authorities soon. The company expects to bring a novel treatment to people suffering with this serious disease who presently have limited options.        

Earlier in July of 2018, the U.S. FDA (Food and Drug Administration) granted Tecentriq-Avastin combination the BTD (Breakthrough Therapy Designation) in hepatocellular carcinoma on the basis of data collected from a currently ongoing Phase Ib clinical trial.

Genentech has made an extensive development program specially for Tecentriq, which includes several planned and ongoing Phase III studies, in skin, gynecological, gastrointestinal, breast, genitourinary, lung, neck and head cancers. This also includes trials evaluating Tecentriq in combination with other medicines as well as alone.     

Earlier in September, the biotechnology firm had announced its plan to double its workforce from 15,000 to 30,000 workers under its expansion plan.

 

Source credit: https://www.gene.com/media/press-releases/14818/2019-10-20/genentechs-tecentriq-in-combination-with



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...